GLYCGippsland Lakes Yacht Club (Victoria, Australia)
GLYCGull Lake Yacht Club (Minnesota)
GLYCGrand Lagoon Yacht Club (Pensacola, FL)
GLYCGreat Lakes Youth Conference (Michigan)
GLYCGrupo en Lógica y Computabilidad
References in periodicals archive ?
(NASDAQ: GLYC) has appointed Scott Jackson, former chief executive officer of Celator Pharmaceuticals, Inc., to its board of directors, the company said.
Total death (n = 915) Glyc A 1.27 1.17 (1.19-1.35) (1.09-1.25) <0.0001 <0.0001 hsCRP 1.13 1.07 (1.07-1.2) (1-1.14) <0.0001 0.0398 IL-6 1.26 1.2 (1.2-1.32) (1.14-1.26) <0.0001 <0.0001 D-dimer 1.09 1.08 (1.06-1.13) (1.04-1.12) <0.0001 <0.0001 B.
Limited Tenders are invited for Supply of Pr Gauges : Glycerine filled pressure gauge-0- 40 kg/cm2,type: direct, mounting: lo cal, dial size: 150 mm.,case: ss 304, ring: standard, fill fluid: glyc erine, lens: shatterproof glass, element: bourdon, bourdon mat.: aisi 316 ss, movement mat.: aisi 304 ss, accuracy:+/-1% or better, ext scre w mat.:ss, pointer type:micrometer, zero:adjust: yes, integral damping screw: yes, wetted parts: ss 304
* GlycoMimetics Inc (NASDAQ: GLYC)(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
After surveying 25 sickle cell disease experts, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC) and Global Blood Therapeutics (GBT) into their upcoming catalysts.
(NASDAQ: GLYC) has dosed first patient in the company's Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML, the company said.
Hubert Vesper: TG are determined by measuring glyc erol after hydrolysis of TG.
* Piper Jaffray downgraded the previous rating for GlycoMimetics Inc (NASDAQ: GLYC) from Overweight to Neutral.
After speaking to a practicing hematologist and emergency medicine doctor at a leading medical institution, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC) and Global Blood Therapeutics (GBT).
(NASDAQ: GLYC) intends to offer and sell, subject to market conditions, 4.5m shares of its common stock in an underwritten public offering, the company said.
(16.) GISSI-3: Effects of lisinopril and transdermal glyc eryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.
GlycoMimetics, Inc.(NASDAQ: GLYC) shares tumbled 61% to $3.59 after the company announced Pfizer's Phase 3 clinical trial evaluating Rivipansel in Sickle Cell did not meet its Primary or key Secondary endpoints.